# SNYR earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/SNYR) · [Earnings tab](https://www.lopjlb.com/stock/SNYR?tab=earnings) Updated: 2026-08-27T06:12:18 Quarters analyzed: 2 ## Cross-quarter narrative Across the two CallCards, Synergy CHC moved from a growth‑focused narrative in Q3 2025—highlighting 12% revenue expansion, gross‑margin improvement to 70.9%, new distribution agreements and a $4.4M equity raise—to a more constrained outlook in Q4 2025, where a loss was reported due to one‑time charges and the termination of a UAE/Turkey license. Management tone remained modestly positive (0.60) while analyst pressure rose (0.40 to 0.50) and uncertainty increased (0.50 to 0.60). Demand signals shifted from broadening retail footprint to strong visibility for beverage RTD sales and a newly launched Mexico subsidiary. Margins, previously buoyed by supplement price hikes, were later described as pressured but expected to stabilize. Capital dynamics reversed: cash fell to $2.6M with higher inventory and professional fees, contrasting with the earlier equity infusion earmarked for rollout. Several distribution milestones stayed on track, but new risks emerged—geopolitical instability affecting licenses, competitive TV advertising pressure, weight‑loss market headwinds, and heightened liquidity concerns—while inventory risk persisted throughout both periods. ## Latest CallCard · Q4 Synergy CHC posted a loss driven by one‑time items and a terminated UAE/Turkey license, but highlighted Mexico subsidiary launch, growing beverage RTD sales and plans to restart TV ads for 2026. **Guidance:** vague — Management gave qualitative outlook for 2026 growth but no specific revenue or margin guidance. **Tone:** mgmt 0.6 · Q&A pressure 0.5 · divergence 0.4 Prepared remarks highlighted strategic progress, international expansion and a foundation for long‑term growth. ### Demand visibility Strong visibility for beverage distribution and Mexico market Millions of RTD cans ready, shipments to Costco Mexico, new distributors EG of America, Wakefern, and upcoming Costco and BJ's roadshows. ### Margins / costs Margin pressured by one‑time items but expected to be stable Q4 gross margin 36.6% down due to license termination and inventory write‑off; normalized margin would be ~68.8%; management expects margin to maintain or increase. ### Capital allocation Cash increased to $2.6M; higher inventory and professional fees for corporate development Working capital surplus $1.78M, inventory $3.7M, professional fees driving operating expense rise. ### Milestones - **UAE/Turkey license termination** [delayed]: License agreement ended due to regional instability, $2.5M revenue reversed. - **Mexico subsidiary launch** [delivered]: Wholly owned subsidiary formed and first shipments to Costco Mexico began. - **Beverage RTD sales 2026 run rate** [on_track]: Q1 2026 generated $600k, establishing $2.5M annual run rate. - **TV advertising restart** [new]: Planned for 2026 to drive same‑store sales lift of ~15%. - **Flat Tummy product line** [at_risk]: Continuing decline, strategic decision pending. - **Core supplement expansion** [on_track]: Shipped 3 new SKUs to 1,600 Kroger locations. - **Costco roadshow** [new]: Planned 2026 roadshow to boost beverage distribution. - **BJ's roadshow** [new]: Planned 2026 roadshow for beverage growth. ### Fears / risks - **Geopolitical risk**: License termination in UAE/Turkey due to regional instability. - **Competitive pressure**: Competitors’ heavy TV advertising may limit same‑store sales growth. - **Product demand shift**: Weight‑loss market impacted by GLP‑1 drugs, hurting Flat Tummy sales. - **Liquidity risk**: Cash balance $2.6M and ongoing operating losses raise cash flow concerns. - **Inventory risk**: Inventory rose to $3.7M, risk of obsolescence. - **One‑time expense exposure**: Large allowances for bad debt and prepaid media credits affect results. ### Key quotes > “While 2025 was a year of transition in many areas of our business, it was also a year of meaningful strategic progress that sets an important foundation for sustainable long-term growth.” > “During 2025, we established our wholly owned subsidiary in Mexico. And in December, we initiated our first product shipments to Costco, Mexico.” > “We anticipate gross margin to maintain its current level or increase.” — Jaime Fickett > “Flat Tummy continues to decline. The weight loss business is being heavily impacted by the GLP1s.” — Jack Ross > “We just raised the money to actually build the inventory in August and to actually get the inventory built takes time, meaning 8 to 12 weeks to build the inventory. So we just really received the majority of the RTD inventory in-house in” — Jack Ross ## Quarter one-liners - **2025 Q4:** Synergy CHC posted a loss driven by one‑time items and a terminated UAE/Turkey license, but highlighted Mexico subsidiary launch, growing beverage RTD sales and plans to restart TV ads for 2026. - **2025 Q3:** Synergy CHC posted 12% revenue growth, improved gross margin to 71%, added key distribution partners and leadership, raised $4.4M equity, and highlighted expanding beverage and supplement rollouts while noting modest beverage revenue and future G&A spend. ## Theme arcs - **Financial performance** (deteriorating): Revenue growth in Q3 turned to a loss in Q4 due to one‑time items and license termination - **Distribution network** (improving): New agreements in Q3 and Mexico subsidiary launch in Q4 expanded retail reach - **Gross margin** (stable): Margin rose to 70.9% in Q3; Q4 expects stability despite one‑time pressures - **Liquidity** (deteriorating): Cash decreased to $2.6M and operating losses raised cash‑flow concerns - **Advertising strategy** (new): TV advertising restart announced for 2026 after a pause in 2025 - **Weight‑loss segment** (deteriorating): Flat Tummy line flagged as at‑risk amid GLP‑1 drug impact - **Geopolitical exposure** (deteriorating): UAE/Turkey license terminated due to regional instability ## Fear persistence - **Inventory risk** [recurring]: Inventory rose from 3M to 3.7M cans, risk of excess noted in both quarters - **Geopolitical risk** [new]: License termination in UAE/Turkey highlighted regional instability - **Competitive pressure** [new]: Heavy TV advertising by rivals may limit same‑store sales growth - **Product demand shift** [new]: Weight‑loss market impact from GLP‑1 drugs affecting Flat Tummy sales - **Liquidity risk** [new]: Cash balance of $2.6M and ongoing losses raise cash‑flow concerns ## Guidance path 2025 Q3:vague → 2025 Q4:vague --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/SNYR`